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Abstract 
 
Lesley M. Smith 
Communicating Data Visually: Data Presentation Formats at  
U.S. Food and Drug Administration  
Drug Advisory Committee Meetings  
(Under the direction of Anne Johnston) 
 
 This thesis investigated the use of tables and graphs to present quantitative data at 
U.S. FDA drug advisory committee meetings.  A total of 7, 422 slides presented at such 
meetings in 2010 comprised the sample.  All slides were coded for slide type; slides 
displaying graphs were also coded for graph type. Analyses were conducted to determine 
differences in data presentation format between the FDA and drug sponsors, slides shown to 
different types of advisory committees, and slides shown at meetings held for different 
purposes. 
 The study found that tables and graphs are used in almost equal measure at drug 
advisory committee meetings. However, the FDA is more likely than drug sponsors to 
display data in tables versus graphs.  The study also found that the most prevalent graph 
formats are bar graphs, forest plots, line graphs, and Kaplan-Meier curves.  Only one slide, 
shown by a drug sponsor, displayed a pictograph. 
  
iv 
 
 
Acknowledgements 
 
 Gratitude and recognition belong to my thesis committee: Dr. Anne Johnston, Dr. 
Lois Boynton, and Dr. Wayne Jack Wallis; to my coder, Andrea Simpson; and to my 
classmates, family, and friends.  Thank you. 
  
v 
 
 
Table of Contents 
 
List of Tables ..................................................................................................................... vii 
List of Abbreviations ........................................................................................................... ix 
Introduction ...........................................................................................................................1 
Literature Review ..................................................................................................................3 
Cognitive Fit Theory ..........................................................................................................7 
Perception ........................................................................................................................ 13 
PowerPoint/Projection Research and Dual-Coding Theory ............................................... 17 
Summary ......................................................................................................................... 18 
FDA Advisory Committee Meetings: Background and Overview ........................................ 20 
FDA Advisory Committee Overview ............................................................................... 20 
Pre-Meeting Materials ..................................................................................................... 22 
Conduct of a Meeting....................................................................................................... 23 
Previous Advisory Committee Research .......................................................................... 24 
Summary ......................................................................................................................... 25 
Research Questions ............................................................................................................. 27 
Method ................................................................................................................................ 28 
Sample ............................................................................................................................. 28 
Availability of Materials .................................................................................................. 30 
Initial Coding ................................................................................................................... 30 
Content Categories........................................................................................................... 31 
Coding ............................................................................................................................. 36 
vi 
 
Coder Training................................................................................................................. 36 
Intercoder Reliability Sample and Testing ........................................................................ 37 
Coding Procedures ........................................................................................................... 38 
Results ................................................................................................................................ 40 
Research Question 1: Prevalence of Data Presentation Formats........................................ 40 
Research Question 2a: Results by Presenter (FDA/Sponsor) ............................................ 44 
Research Question 2b: Results by Committee .................................................................. 45 
Research Question 2c: Results by Meeting Purpose ......................................................... 49 
Discussion and Conclusions ................................................................................................ 51 
Tables versus Graphs ....................................................................................................... 51 
Graph Type ...................................................................................................................... 53 
Limitations ...................................................................................................................... 55 
Conclusions ..................................................................................................................... 55 
Appendix A ......................................................................................................................... 60 
Appendix B ......................................................................................................................... 66 
References ........................................................................................................................... 93 
 
  
vii 
 
List of Tables 
 
Table 
1. Definitions and Examples of Common Presentation Formats………………………...6 
2. Conclusions Regarding Best Format for Presentation of Gist or Verbatim 
Information…………………………………………………………………………..11 
 
3. Length of Presentations………………………………………………………………28 
4. Slides by Type (Overall)……………………………………………………………..39 
5. Data Slides by Type (Overall)……………………………………………………….40 
6. Original Distribution of Graphs by Type (Overall)………………………………….41 
7. Graphs by Type (Overall)……………………………………………………………42 
8. Data Slides by Type (by FDA/Sponsor)……………………………………………..43 
9. Data Slides by Type (by Meeting Purpose)………………………………………….48 
viii 
 
List of Figures 
 
Figure  
1. FDA Advisory Committee Meeting Room Setup……………………………………21   
2. EMDAC Page from fda.gov…………………………………………………………29   
3. Example of Text and/or Bullets in Table Form……………………………………...32  
4. Example of a Build Sequence………………………………………………………..32 
5. Initial Code Sheet Questions…………………………………………………………37 
6. Primary Code Sheet Questions………………………………………………………38 
7. Pictograph……………………………………………………………………………42 
8. Graphs by Type (by FDA/Sponsor)………………………………………………….44 
9. Data Slides by Type (by Committee)………………………………………………...46 
10. Graphs by Type (by Committee)…………………………………………………….47 
11. Graphs by Type (by Meeting Purpose)………………………………………………49 
 
ix 
 
List of Abbreviations 
 
2D   Two dimensional 
3D   Three dimensional 
AIDAC  Anitinfectives Drugs Advisory Committee 
CRDAC  Cardiorenal Drugs Advisory Committee 
DSaRM  Drug Safety and Risk Management Advisory Committee 
EMDAC  Endocrinologic and Metabolic Drugs Advisory Committee 
FDA   Food and Drug Administration 
GDAC   Gastrointestinal Drugs Advisory Committee 
NASA   National Aeronautics and Space Administration 
NDA   New Drug Application 
ODAC   Oncologic Drugs Advisory Committee 
Perip. C. Nerv. Peripheral and Central Nervous System Drugs Advisory Committee 
Psychopharm  Psychopharmacologic Drugs Advisory Committee 
Pul. Allergy  Pulmonary Allergy Drugs Advisory Committee 
Repro. Health  Reproductive Health Drugs Advisory Committee 
 
 
  
 
Introduction 
 Corporate communication is the exchange of information between a business and its 
publics (Huang & Kleiner ,2005). Companies must communicate effectively in order to 
remain competitive in the marketplace (Huang & Kleiner,2005). As case studies have shown, 
failure to communicate effectively may lead to stock devaluation and unwanted attention 
from outside stakeholders (Reese, 2001). 
 Effective communication does not simply mean exposing an audience to information, 
but also making sure that information is received, comprehended, agreed with, retained, and 
retrieved (McGuire, 1976).   In order to allow audiences to travel through these steps, 
companies must focus not just on what they communicate but also how they communicate.  If 
a communication format does not allow an audience to travel through the steps of 
information processing, it is not effective.   
 Research into the communication of quantitative data has focused on whether such 
data are communicated more effectively via tables or graphs, and, if graphs, what type.  Such 
research has demonstrated that decisions regarding data—the ―agreed with‖ step of effective 
communication—vary depending on the format in which it is presented (Tait et. al, 2010). 
 The purpose of this research is to determine how quantitative data are presented at 
FDA advisory committee meetings.  An advisory committee is a panel of independent 
experts who advise the FDA regarding drug safety and effectiveness (U.S. FDA, 2010d).  
Committee advice is delivered following oral and slideshow presentations by pharmaceutical 
companies and the FDA, and that advice affects the availability of prescription and over-the-
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counter drugs in the United States.  If a company cannot convey information effectively at an 
advisory committee meeting, it risks failure to obtain new drug approval, placement of 
additional label restrictions on approved drugs, and drops in stock valuation.  And, while a 
pharmaceutical company‘s primary audience at advisory meetings is the committee itself, 
other important publics such as the FDA, the news media, and investors also hear the 
company‘s messaging at these meetings.   
 There are three theories prevalent in the literature regarding data presentation formats.  
Those theories—cognitive fit, perception, and dual-coding—provide a foundation for the 
following investigation into data presentation formats at FDA advisory committee meetings. 
  
 
Literature Review 
 Presenters, such as those speaking to advisory committees, need a scientific basis for 
their choice of data presentation format (Cleveland & McGill, 1984).  Unfortunately, the 
number of variables involved in graphical data display and different approaches to studying 
each—without concurrence as to what the theoretical foundations for data presentation 
research should be—make it difficult to establish what that scientific foundation should be 
(Ancker et al., 2006; Arunachalam et al., 2002; Cleveland & McGill, 1984; Feldman-Stewart, 
et al., 2007; Price et al., 2006; Smerecnik et al., 2010; Speier, 2006; Tait et al., 2010; Vessey, 
1991).   
 Some researchers have investigated which type of data presentation format is most 
effective (Cleveland & McGill, 1984; Elting et al., 1999; Feldman-Stewart et al., 2007; 
Hawley et al., 2008; Schapira et al., 2006; Smerecnik et al., 2010; Speier, 2006; Tait et al., 
2010; Vessey, 1991), while others have focused on which elements of design within formats 
are most effective (Arunachalam et al., 2002; Feldman-Stewart et al., 2007; Mackiewicz, 
2007; Price et al., 2007; Stewart et al., 2009).  Difficulty applying the results of these studies 
arises, in part, because the outcomes measured in display research vary: accuracy (Elting et 
al., 1999; Feldman-Stewart, et al., 2007; Price et al., 2006; Speier, 2006), knowledge 
(Hawley et al., 2008; Tait et al., 2010), comprehension (Price et al., 2006; Stewart et al., 
2009), response times (Feldman-Stewart et al., 2007; Price et al., 2006), perception (Hawley 
et al., 2008; Mackiewicz, 2007; Schapira et al., 2006; Tait et al., 2010) format preference 
(Price et al., 2006; Schapira et al., 2006), and more have all been used as outcome measures.  
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Further complicating things is that even when outcome measures are similar, findings vary 
(Ancker et al., 2006; Feldman-Stewart et al., 2007; Smerecnik et al., 2010; Vessey, 1991).  
Write Feldman-Stewart et al. (2007), ―when comparing performance using graphs to that 
using tables, there is evidence that graphs lead to better performance, equal performance, and 
poorer performance than tables‖ (p. 35).  Some researchers theorize that the differences in 
findings result from difference in the tasks research participants are asked to perform with the 
data (Ancker et al., 2006; Arunchalam et al., 2002; Feldman-Stewart et al., 2007; Vessey, 
1991), while others do not comment on it at all.   
 Despite this murkiness, several themes have emerged from the literature, including 
cognitive fit theory (Baker et. al, 2009; Feldman-Stewart et al., 2007; Hawley et al., 2008; 
Speier, 2006; Tait et al., 2010; Vessey, 1991), perception (Baker et. al, 2009; Cleveland & 
McGill, 1984; Price et al., 2006; Speier, 2006; Tait et al., 2010; Vessey, 1991), and dual-
coding theory (Mackiewicz, 2007; Tait et al., 2010; Vessey, 1991).  The approach taken here 
is to review each of these themes in turn, since inclusive research is limited.   
 First, a review of cognitive fit theory will reveal the importance of taking into 
consideration how data will be used when selecting a display format.  Next, a discussion of 
perception theory will explain how viewers obtain data when they look at a table or graph, 
and, finally, an exploration of dual-coding theory will show how researchers think graphs 
should be designed when used as part of an oral presentation.  Together, these three theories 
provide a framework within which to consider the most-effective format for data presentation 
at FDA advisory committee meetings.   
 First, a note regarding terminology: most of the research reviewed here utilized 
different versions of each data presentation format.  Bar graphs studied by Hawley et al. 
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(2008), for example, vary slightly from bar graphs studied by Schapira et al. (2006).  Some 
researchers used bar graphs with axes and some did not, some researchers used bar graphs 
with multiple bars and some did not, etc.  Some researchers used similar display formats as 
others, but referred to the formats by different names.  For example, Ancker et al. (2006) 
studied the ―icon array,‖ a type of display more commonly referred to as a pictograph (p. 
610).  Here, for clarity, the same terms will be used to refer to similar formats regardless of 
the terminology the original researcher used.  Table 1 offers general definitions and 
representative examples of commonly studied formats.  Keep in mind that the actual formats 
studied by each researcher may vary for the examples shown in the table.   
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Table 1  
Definitions and Examples of Common Presentation Formats 
Presentation  
Format 
Representative  
Definition 
Representative  
Example 
Bar graph  
 
―A graph consisting of vertical or 
horizontal bars whose lengths are 
proportional to amounts or 
quantities‖1 
 
 
Stacked bar graph Similar to a bar graph, except each 
bar is divided into sections to 
represent the different variables. 
 
 Pictograph with 
consecutive shading 
―An icon array [most commonly 
referred to in the literature as a 
pictograph] portrays a risk at the 
discrete level of measurement as a 
group of individual icons, such as 
dots or stick figures‖  
(Ancker et al., 2006,  
p. 610). 
 
Pictograph with  
random shading 
 
Pie chart A chart that consists of a circle 
divided into two or more sections 
by radii of the circle.  The size of 
the sections indicates the size of 
the variables they represent.   
 
Sparkline ―Small, high-resolution graphics 
usually embedded in a full context 
of words, numbers, images;‖ they 
are ―word-sized graphics‖ (Tufte, 
2001, p. 171). 
Refer to Tufte, 2001 
                                               
1 http://dictionary.reference.com/browse/BAR+GRAPH 
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Cognitive Fit Theory   
 The discrepancies in the literature regarding whether tables or graphs—and which 
type of graph—are the best format for data presentation may be explained through cognitive 
fit theory (Feldman-Stewart et al., 2007; Vessey, 1991).  Cognitive fit theory posits that 
presentation format should be determined by the task at hand; that is, that the format and the 
task the viewer is asked to perform with the data should ―fit‖ (Vessey, 1991).   
 The most-effective choice of format is the one that matches the nature of the task 
(Ancker et al., 2006; Arunachalam et al., 2002; Smerecnik et al., 2010; Speier, 2006; Vessey, 
1991).  If, for example, tables convey specific numerical values more effectively than graphs 
do—and the viewer needs to garner specific numerical values from a display—then a table is 
a better cognitive fit for that task than a graph is. Confusion has arisen as to which display 
formats are most effective because different researchers have investigated formats in the 
context of varied tasks (Feldman-Stewart et al., 2007; Vessey, 1991).  This practice has led 
Vessey (1991) to conclude that a ―taxonomy‖ of tasks should be established to prevent 
apparent conflicts among research findings in this field.   
 Task type.  Typical characterizations of task types in the literature include spatial 
versus symbolic tasks (Speier, 2006; Vessey, 1991), gist versus verbatim knowledge (Hawley 
et al., 2008; Tait et al., 2010) and situation model versus text base level knowledge 
(Smerecnik et al., 2010).   Although they use different terminology, the nature of each pair of 
characterizations is similar.  Tasks are characterized ―based on the type of information that 
facilitates their solution‖ (Vessey, 1991, p.219).  Spatial, gist, or situation model tasks 
require the audience to evaluate relationships between variables (Vessey, 1991).  Symbolic, 
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verbatim, or text base level tasks require the audience to extract specific data values from a 
display (Vessey, 1991).   
 Tufte (1997) provides a clear example of a spatial task and cognitive fit theory.  In an 
analysis of the decision to launch the space shuttle Challenger in 1986, which blew up  
78 seconds into launch, he determined that there was a ―scandalous discrepancy between the 
intellectual tasks at hand and the images created to serve those tasks‖ (p. 45).  Specifically, 
engineers tried to communicate to NASA that low temperatures on the day of the launch 
might lead to failure of the shuttle‘s O rings.  However, none of the visual aids created by the 
engineers displayed temperature and likelihood of failure together—a poor cognitive fit for 
the goal of establishing a causal relationship between the two variables.     
Like tasks, data presentation formats themselves can be categorized as either spatial 
or symbolic.  Intuitively, graphs are spatial representations and tables are symbolic 
representations (Smerecnik et al., 2010; Vessey, 1991).  Thus, the prevailing theory is that 
graphs are the best format for spatial tasks and tables are the best format for symbolic tasks 
(Smerecnik et al., 2010).   
 Empirical testing. Hawley et al. (2008) and Tait et al. (2010) empirically tested the 
fit between data presentation format and task.  Both studies were conducted in the context of 
health risk communication.  Participants viewed benefit/risk data for two drugs—one of 
which was medically superior—and asked to make a choice between them (Hawley et al., 
2008; Tait et al., 2010).   
 The primary outcome measures for both studies were verbatim knowledge (―actual 
numerical knowledge‖) and gist knowledge (―overall impression‖) (Tait et al., 2010, p. 489).  
Hawley et al. (2008) investigated the impact of (1) pie charts, (2) bar graphs, (3) pictographs, 
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(4) sparklines, (5) modified pie charts, and (6) tables on knowledge, while Tait et al. (2010) 
investigated (1) pictographs, (2) tables, and (3) text.  Participants were tested for gist and 
verbatim knowledge after viewing the data and asked to make a choice between treatments 
for themselves (Hawley et al., 2008) or for their child (Tait et al., 2010) in a fictional medical 
scenario.  Secondary measures of perception were also evaluated (Hawley et al., 2008; Tait et 
al., 2010).   
 Feldman-Stewart et al. (2007) similarly studied the impact of data presentation 
formats on hypothetical cancer treatment decisions.  They did not test cognitive fit theory 
explicitly, but they did evaluate display formats in the context of gist knowledge (Feldman-
Stewart et al., 2007).  Primary outcomes were (1) accuracy in choosing the treatment option 
with the best chance of survival, (2) accuracy in choosing the treatment option with the 
smaller chance of side effects, and (3) response times among participants randomized to view 
the various display format. 
 Feldman-Stewart and colleagues had previously conducted research into gist and 
verbatim information, studying the impact of pie charts, vertical bars, horizontal bars, 
numbers, and pictographs with oval icons (with either consecutive or random shading) 
(Feldman-Stewart et al., 2007).  They concluded from that research that different formats 
were in fact better for conveying gist versus verbatim information, and thus, ―performance is 
task dependent‖ (p. 35).  Specifically, vertical bar graphs, followed by pictographs with 
consecutively shaded icons, were best for conveying gist information.  Text, followed again 
by pictographs with consecutively shaded icons, was best for conveying verbatim 
knowledge.   The findings from this earlier research led to the conclusion that ―the best way 
to present risk information for treatment decisions‖ either (a) incorporates vertical bars and 
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numbers, or (b) uses pictographs with consecutively shaded icons (p. 35).  Subsequent 
research by the same authors was intended to investigate option A.   
 The follow-up study evaluated the same presentation formats as the earlier research; 
however, three ―add-on conditions‖ evaluated the incorporation of numbers with each format 
(Feldman-Stewart et al., 2007, p. 50).  The conditions, applied to each of the six formats, 
were: (1) the addition of the numeric value as text, (2) the addition of a scale, or (3) the 
addition of both the numeric value and a scale.  Graph colors were also evaluated in this 
study, either black and white or blue or yellow, with either a white or blue background.   
 The Hawley et al. (2008) and Tait et al. (2010) studies were controlled for numeracy 
(the capacity for quantitative thought and expression,
2
 also, quantitative literacy).  The results 
for high and low numeracy individuals as well as results in the aggregate were reported.  The 
findings for participants with high numeracy are likely the most relevant here.   
 The findings differed slightly among the three studies (Feldman-Stewart et al., 2007; 
Hawley et al., 2008, Tait et al., 2010).  Hawley et al. (2008) found the highest verbatim 
knowledge, regardless of numeracy, with those randomized to view the table.  They found 
the highest levels of gist knowledge, regardless of numeracy, with those randomized to view 
the pie chart.  Tait et al. (2010) found the highest levels of both types of knowledge, 
regardless of numeracy, with those randomized to view the pictograph.  Feldman-Stewart et 
al. (2007), who only studied gist knowledge, found that vertical bars with scales led to the 
fastest and most-accurate responses.  Additionally, neither foreground nor background color 
were found to impact knowledge (Feldman-Stewart et. al 2007).   
 All three groups of researchers, despite seeing different findings, reached similar 
conclusions.  The findings are summarized in Table 2.  The pictograph was the most-
                                               
2 http://www.merriam-webster.com/dictionary/numeracy 
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effective format tested by Tait et al. (2010), but not by the other researchers.  However, the 
pictograph was the second most-effective format for conveying both types of information in 
the Hawley et al. (2008) and the Feldman-Stewart et al. (2007) studies.  Consequently, all 
three groups of researchers assert that the pictograph may be the optimal format for 
presentation of medical benefit/risk information.  Medical treatment decisions often require 
both gist and verbatim knowledge, and the pictograph effectively communicates both.  
Table 2   
Findings Regarding Best Format for Presentation of Gist or Verbatim Information 
 Feldman-Stewart  
et al. (2007) 
Hawley et al. 
(2008) 
Tait et al. 
(2010) 
Gist information 
Vertical bars  
with scales 
Pie charts Pictographs 
Verbatim 
information 
Not studied Tables Pictographs 
Both gist  
and verbatim 
information 
Pictographs with 
consecutive shading 
Pictographs N/A 
  
 Task complexity.  An additional concept associated with cognitive fit theory is task 
complexity (Speier, 2006). The idea here is that not only task type, but also the complexity of 
that task informs fit.  Tasks are either simple or complex.  Simple tasks require only the 
acquisition of information (Vessey, 1991).  Complex, decision-making tasks also require the 
acquisition of information and an evaluation of that information (Speier, 2006; Vessey, 
1991).  Complex information must be processed by the audience in some way (Speier, 2006).   
 Speier (2006) investigated how data presentation format influences both simple and 
complex tasks.  Her research used cognitive fit theory as a foundation, and thus considered 
task type—spatial or symbolic—as well as task complexity.  This design led to the 
12 
 
investigation of four categories of tasks: spatial-simple, spatial-complex, symbolic-simple, or 
symbolic-complex.   
 Spatial tasks require perceptual cognitive processes (Speier, 2006; Vessey, 1991).  
That is, they are solved through ―immediate or intuitive recognition‖3.  Symbolic tasks 
require analytical cognitive processes—they are solved through study and analysis. 
However, Speier hypothesized that there is a ―crossover point‖ at which tasks become so 
complex that decision makers turn to intuitive perceptual processes to solve analytic 
symbolic-complex tasks (p. 1120).  Thus, at a given level of complexity, spatial graphs 
become more helpful than symbolic tables in solving symbolic tasks.  This means that 
cognitive fit is moderated by task complexity. 
 Speier (2006) measured the timing and accuracy of decisions in experimental tests of 
her hypotheses.  Participants evaluated warehouse location and workload scheduling data 
presented in either tables or bar graphs.  The results were generally consistent with cognitive 
fit theory—for all spatial tasks, graphs led to superior accuracy and decision time versus 
tables.  For symbolic-simple tasks, such as comparisons between machine capacity and 
scheduling, tables were expectantly superior versus graphs for accuracy but not for decision 
time—a result inconsistent with cognitive fit theory.  However, for symbolic-complex tasks, 
such as comparisons of cost across six periods to the lowest possible cost, tables and graphs 
led to equivalent accuracy and timing.  Speier concludes that this finding results from 
increased reliance on perceptual processes as complexity increases, as hypothesized.  The 
ultimate conclusion is that cognitive fit theory should be extended to state that ―as task 
complexity increases, decision-makers appear to rely more heavily on their perceptual 
                                               
3 http://dictionary.reference.com/browse/perception 
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processes such that the use of spatial information presentation formats allows for equivalent 
decision accuracy (at the task level) with symbolic formats‖ (p. 1126).  
 In summary, cognitive fit theory purports that, in order to display data effectively, one 
must take into account how the data will be used.  Although it is difficult to draw conclusions 
from the varied research that has been conducted, graphs seem to be a better fit than tables 
for tasks that require gist knowledge.  However, if specific data values need to be conveyed, 
tables may be a better cognitive fit than graphs.  Because some tasks require both gist and 
verbatim knowledge and because fit may be moderated by task complexity, however, it may 
be best to use a display format that conveys both types of knowledge effectively. 
Perception    
Baker et al. (2009) believe that research into which type of graph is most effective 
should extend beyond cognitive fit theory.  They agree that most graphs are spatial 
representations and thus have a good cognitive fit with spatial tasks.  They turn to graphical 
perception theory for exploration of the perceptual cognitive processes that spatial tasks call 
for.   
Cognitive fit theory focuses on how information gleaned from a display is processed 
by an audience after it is received—what the viewer does with the information.  Perception 
theory, on the other hand, focuses on how that information is conveyed in the first place—
how the viewer obtains the information (Baker et al., 2009, McGuire, 1976).  Baker et al. 
theorize that a data display format is effective if the individual parts of the display—say the 
bars or the pie pieces that represent variables—help the viewer acquire information.  
 Perception theory. Perception, with regard to information presentation formats, has 
been approached from a variety of ways.  Cleveland and McGill (1984), statisticians whose 
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work on graphical communication is cited extensively, worked with a goal of establishing a 
―science of graphical perception‖ (p. 537).  They focused on both theory and experimental 
tests of theory to do so.  Baker et al. (2009) also studied graphical perception from a 
theoretical perspective.  Other researchers, however, have tested how graphs are perceived 
without explicitly linking their research to perception theory (Hawley et al., 2008; 
Mackiewicz, 2007; Schapira et al., 2006; Tait et al., 2010).  Those studies investigate the 
perception of conclusions, such as how scientific the presentation format is, derived after 
viewing graphical or tabular displays of data. 
Cleveland and McGill (1984) define ten ―elementary perceptual tasks‖ that are 
fundamental to ―extracting quantitative information from graphs‖ (p. 532).  Consider how a 
viewer derives the value of a variable displayed on a bar graph.  He or she perceives where 
the bar that represents the variable ends in relation to the graph‘s axis.  Cleveland and McGill 
call this activity the ―perception of position along a common scale,‖ one of their ten 
perceptual tasks.  The other nine tasks are position along non-aligned scales (as with two bars 
with different size axes), length, direction, angle, area, volume, curvature, shading, and color 
saturation.  A viewer of a graph perceives the length of a bar, the shading of icons, or the 
angle of pie pieces, and is able to determine the value of the data based on these perceptions. 
Similarly, Bertin (as cited in Baker et al., 2009, p. 540) identified four ―visual perceptual 
approaches‖ that allow for perception and comparison of variables on a graph.  The four 
approaches are association, dissociation, perception of order and perception of quantity.  
Both groups of researchers (Baker et al. 2009; Cleveland & McGill, 1984) recognize 
that different types of graphs naturally elicit performance of different perceptual tasks; for 
example, pie charts elicit perception of angle and bar graphs elicit perception of position 
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along a scale (Baker et al., 2009; Cleveland & McGill, 1984).  Note that some types of 
graphs lead to the performance of more than one of these tasks, such as a pie chart, which 
naturally leads to perception of angle, curvature, and volume.   
Cleveland and McGill (1984) theorize that some of the perceptual tasks lead to a 
more-accurate understanding of the underlying quantitative data than others.  Thus, some 
formats—the ones that elicit those tasks—are superior to others.  For example, the value of a 
variable represented by position along a common scale (e.g., with a bar graph) is 
theoretically more easily discernible than the value of a variable represented by angle (for 
example, with a pie chart).  Cleveland and McGill suggest that the perceptual tasks, from 
most to least accurate, are: position (common scales), position (non-aligned scales), length, 
direction, angle, area, volume, curvature, and shading.   Baker et al. (2009) hypothesize that 
the more a graph encourages the four visual perception approaches, the more effective it is as 
a format for the presentation of information.   
Cleveland and McGill (1984) conducted two experiments to test their theory; Baker et 
al. (2009) did not conduct empirical research, but suggested experimental designs that may 
be useful in doing so.  The Cleveland/McGill experiments evaluated bar graphs, stacked bar 
graphs, pie charts, and statistical maps with shading.  Judgments of data values that were 
based on the perception of position were more accurate than judgments based on perception 
of length in the first experiment and more accurate than perception of angle in the second 
experiment.  The researchers, however, ultimately argue for the use of three alternative 
information presentation formats that were not evaluated in their study—the dot chart, dot 
chart with grouping, and framed-rectangle chart.  The rationale behind their recommendation 
is that these formats elicit perceptual tasks that are higher in the ordering of effectiveness 
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than other formats.  Tasks, and thus formats, that lead to a more-accurate understanding of 
the data should be used whenever possible.  However, Cleveland and McGill do note that 
―the ordering of the perceptual tasks does not provide a complete prescription for how to 
make a graph.  Rather, it provides a set of guidelines that must be used with judgment in 
designing a graph‖ (p. 552).   
 Perception as an outcome measure. Several health risk communication researchers 
use perception as an outcome measure in evaluations of data display formats (Hawley et al., 
2008; Mackiewicz, 2007; Price et al., 2007; Schapira et al., 2006; Tait et al., 2010).  These 
studies evaluate not the method of how quantitative values are perceived by the viewer, but 
how viewers perceive some thing, after viewing the graphs, other than the values themselves.  
Examples include conclusions about the data or graph format.  Price et al. (2007) explain this 
interest in conclusions in terms of the goal of health risk communication.  That goal is to 
communicate the level of risk and benefits of a treatment, and thus, interest is in how such 
things are perceived (Price et al., 2007).  For example, in the Hawley et al. and Tait et al. 
research, the perception of the effectiveness of the graphs and trustworthiness of the data was 
measured.   
Additional perception measures have included helpfulness (Tait et al., 2010) and 
truthfulness (Schapira et al., 2006) of display formats and how scientific the format is 
perceived to be (Tait et al., 2010).  As with other outcome measures, findings have varied. 
For example, both the table (Hawley et al, 2008) and the pictograph (Tait et al., 2010) have 
been rated as the most effective, trustworthy, and scientific format.   
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PowerPoint/Projection Research and Dual-Coding Theory 
  Neither cognitive fit nor perception theory address, as a variable, the circumstances 
under which information is viewed.   However, whether graphs and tables are viewed on 
paper without oral narration or via projection while a presenter is speaking likely has an 
impact on what type of display is most effective.   A third theory, dual-coding theory, 
informs the selection of data display format under these circumstances.    
 Communication can be broadly categorized as verbal or nonverbal (Doumont, 2002; 
Paivio, 1991).  Dual-coding theory holds that verbal and nonverbal information is processed 
along separate channels in the brain (Mackiewicz, 2007; Tait, 2010).  The difference between 
the two types of communication is not whether information is received through the eyes 
(visual communication) or the ears (auditory communication) but whether or not language is 
necessary to process the message (Doumont, 2002).  Verbal information cannot be 
understood without language, while nonverbal information can.  Either type of information, 
however, can be communicated via visual or auditory channels.  
 While verbal and nonverbal information are processed via separate channels, they are 
processed simultaneously.  If complementary information is presented via each channel, it 
can aid recall (Doumont, 2002; Paivio, 1991; Tait, 2010).  That is why a visual aid used by a 
presenter can aid recall of information delivered orally.  Complementary verbal (the speech) 
and nonverbal (the visual aid) information is being presented simultaneously.  However, if 
the information being presented simultaneously is of the same type—either verbal or 
nonverbal—it can harm recall.  Such communications would compete for the same cognitive 
resources (Doumont, 2002).  This competition leads some researchers to argue that if 
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information presentation formats meant to serve as visual aids are too verbal, they can 
distract from the overall communication and be less effective.    
 There is far less empirical research into how dual-coding theory informs the use of 
tables and graphs in oral presentations than is needed.  The available research in this area, 
which is a start, demonstrates only that two-dimensional graphs are more effective, from an 
accuracy and comprehension perspective, than three-dimensional graphs (Mackiewicz, 2007; 
Stewart et al. 2009).  Also, Doumont (2002) has used the theory to argue against busy, 
cluttered slides.  
Summary  
 Cognitive fit theory, perception theory, and dual-coding theory are valuable tools to 
determine how data should be displayed.  How the data will be used, how the viewer will 
glean information from the display, and whether the display will be used as an aid to an oral 
presentation should all be taken into account in deciding which format is most effective.  The 
complex number of variables involved in display format research and different approaches to 
studying them, however, make it difficult to draw practical conclusions from the existing 
literature.  Research that might be informative is made less so because it can only be 
narrowly applied to circumstances with the same variables.  
 The difficulties inherent in display format research led Feldman-Stewart et al. (2007) 
to conclude that ―there is virtually no information about what format is best for patients 
making medical treatment decisions‖ (p. 35).  Likewise, due to a lack of specific research 
into how data should be presented (1) when used as a visual aid, (2) during an oral 
presentation, (3) for a medical risk/benefit analysis, there is virtually no information about 
what format is best for FDA/sponsors to use in presentations to external FDA advisors. This 
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thesis, the focus of which is to describe how data is currently presented at advisory 
committee meetings, does not fill the research void.  However, it provides a foundation for 
further research into the field.  An understanding of how speakers currently present data to 
advisory committees is a necessary first step in determining how they should present data. In 
order to explore any of these questions further, an overview of the mechanics of an advisory 
committee meeting is first in order.
  
 
FDA Advisory Committee Meetings: Background and Overview 
FDA Advisory Committee Overview 
  The FDA holds advisory committee meetings to obtain advice from independent 
experts about the safety and effectiveness of food, drugs, veterinary products and other items 
regulated by the agency (U.S. Dept. of Health and Human Services, 2008b; U.S. FDA, 
2009b).  There are 32 different advisory committees, 16 of which provide guidance on drug 
safety and effectiveness (U.S. FDA, 2009a).  Each drug advisory committee focuses on a 
specific area of medicine such as oncology, endocrinology, or cardiovascular health.   
 Advisory committees comprise medical or scientific experts who are able to interpret 
complex data and understand their significance to public health (U.S. FDA 2010b).  Many 
committees also include a patient, consumer, and non-voting pharmaceutical industry 
representative (U.S. FDA, 2010c).  Members serve four-year terms.  Their role is to provide 
advice to the Commissioner of Food and Drugs—the head of the FDA.  As such, they are 
considered Special Government Employees, are paid for their time, and must disclose 
financial and other conflicts of interest. 
 Each drug advisory committee meets approximately four times per year.  The Food 
and Drug Cosmetics Act requires meetings under some circumstances and gives the FDA 
discretion as to when to convene a meeting under others (U.S. Dept. of Health and Human 
Services, 2008b).  The agency outlines three factors it takes into consideration in its decision 
to call a meeting: 
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(1) ―Is the matter at issue of such significant public interest that it would be highly 
beneficial to obtain the advice of an advisory committee as part of the agency‘s 
regulatory decision-making process (U.S. Dept. of Health and Human Services, 2008b, 
p.4)?‖ 
 
(2) ―Is the matter at issue so controversial that it would be highly beneficial to obtain the 
advice of an advisory committee as part of the agency‘s regulatory decision-making 
process (U.S. Dept. of Health and Human Services, 2008b, p.4)?‖ 
 
(3) ―Is there a special type of expertise that an advisory committee could provide that is 
needed for the agency to fully consider a matter (U.S. Dept. of Health and Human 
Services, 2008b, p.4)?‖ 
 
In the past, the agency has called for meetings to consider new drug applications, to consider 
proposed new indications for existing drugs, and to discuss controversy regarding a drug‘s 
risk/benefit profile (U.S. Dept. of Health and Human Services, 2008a; U.S. Dept. of Health 
and Human Services, 2008b,).   
 Committee members consider issues at meetings by listening to presentations from 
the drug sponsor, the FDA, and other interested parties.  Advisory committee meetings are 
intended to be open forums where the public may hear presentations and discussion and 
participate if desired.  The FDA is required to notify the public of a meeting at least 15 days 
in advance and to allow at least one hour during the meeting for public comments (U.S. Dept. 
of Health and Human Services, 2004).  The FDA encourages public participation and holds 
meetings in facilities, such as hotel ballrooms or conference centers, that accommodate 
sizable audiences.  A typical room setup is depicted in Figure 1.  According to FDA guidance 
(U.S. Dept. of Health and Human Services, 2008b), advisory committee meetings ―facilitate 
public discussion of important topics and provide a means for the public to provide 
comments to the agency‖ (p.3). 
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Figure 1. FDA Advisory Committee Meeting Room Setup   
 
Figure 1.  The Great Room of the FDA‘s White Oak Conference Center, set up for an 
EMDAC meeting on December 7, 2010, is indicative of a typical advisory committee 
meeting room setup and size.  Committee members sit at the U-shaped table.  In keeping 
with the public nature of committee discussions, the open end of the table faces the 
audience. Photos ©2010, Celina Mount.  Used with permission. 
 
Pre-Meeting Materials  
 Both the drug sponsors and FDA are required to provide background information on 
an issue before a committee to its members 14 to 21 days in advance of the meeting at which 
it will be discussed (U.S. Dept. of Health and Human Services, 2008a).  According to the 
agency, the amount and type of background information—called a briefing document—
varies based on the purpose of the meeting.  As such, when the FDA notifies a drug sponsor 
that a meeting will take place—approximately 55 days prior to the meeting—it may also 
―advise the sponsor about the information it may wish to include in its briefing materials‖ 
(U.S. Dept. of Health and Human Services, 2008a, p.8).  Importantly, sponsors may only 
include information derived from drug studies and must exclude any information that is 
misleading, promotional, defamatory, irrelevant, or intemperate.  For many drug advisory 
committee meetings, the briefing documents are data driven, lengthy—upwards of 200 
pages—and detailed.   
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Conduct of a Meeting  
 While meeting agendas vary between types of committees, a typical meeting consists 
of  a formal call to order by the committee chairperson, the reading of a conflict of interest 
statement by the committee‘s executive secretary, the sponsor‘s presentation to the 
committee followed by clarifying questions from the committee, the FDA‘s presentation to 
the committee followed by clarifying questions from the committee, the open public hearing, 
questions from the committee to any speaker, and, finally, public discussion and voting by 
the committee (U.S. FDA, CDER, 2010).  Meetings usually last either four or eight hours, 
during which the committee must hear presentations, conduct discussions, and make 
recommendations to the agency. 
 The discussion and voting portions of a meeting are arguably the most important, 
since the intent of an advisory committee meeting is to obtain feedback and opinions from 
the panel members.  Since it is the FDA that calls for the meeting and requests the advice, it 
is also the FDA that determines the topics of discussion.  It does so by posing a series of 
questions to the committee, some of which require only discussion and some of which 
require a vote from the committee.  Voting questions are included in the committee 
members‘ advance briefing material.  The intent is to provide the committee with the 
opportunity to thoroughly review the questions prior to the meeting and ensure thoughtful 
guidance is provided to the FDA at the meeting (U.S. Dept. of Health and Human Services, 
2008a).  The FDA encourages all committee members to take part in the discussion portion 
of the meeting, since such activities ―help inform the agency‘s own deliberations on scientific 
and regulatory matters‘ (U.S. Dept. of Health and Human Services, 2008c, p.4).   
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 In 2008, the agency adopted new voting procedures to ensure the integrity and 
consistency of the voting process (U.S. Dept. of Health and Human Services, 2008c).  The 
guidance elucidates both the question format and the voting process itself.  Voting questions 
should ―have minimal qualifiers, not be leading, and should avoid the use of double or triple 
negatives,‖ and the committee chairperson should clarify any confusion panelists may have 
about a question before a vote is called (p.5)  When it is time to vote, members cast their 
votes simultaneously—versus sequentially—to help prevent influence from the votes that 
have been cast on ones that have not yet been cast.  Votes were often cast sequentially prior 
to the release of the 2008 guidance. 
 All information presented at an advisory committee meeting—whether by the agency, 
the sponsor, the public, or the committee discussion itself—becomes a permanent part of 
public record.  Some information, such as the briefing documents, must be made available to 
the public at least two days prior to a meeting (U.S. Dept. of Health and Human Services, 
2008a).  Other information, such as meeting slides and transcripts, are made available to the 
public following the meeting. 
 The advice a committee gives the FDA is non-binding; however, the agency usually 
follows committee advice—by some accounts, as often as 74% of the time (Herper, 2010).  
Therefore, the substance and conduct of advisory committee meetings are important parts of 
drug safety evaluation in the United States.  On behalf of U.S. taxpayers, the agency spends 
$8 million annually to conduct advisory committee meetings (Nguyen, et al., 2006). 
Previous Advisory Committee Research 
 A 2006 study into the decision-making process at advisory committee meetings 
speaks to the impact of communication at these meetings (Nguyen, Cook, & Bero, 2006).  
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The research entailed a comparative case study of Non-Prescription Drugs Advisory 
Committee meetings where a prescription to over-the-counter drug switch was considered.  
The researchers examined the meeting transcripts, the FDA and sponsor slides, and the 
questions posed by the FDA to the committee to determine the ―extent to which committee 
discussion adhered to‖ the questions asked of the panel by the FDA (p. 1232).   
 Nguyen et al. (2006) found that committee questions about the wording and specific 
meaning of individual words in the FDA questions led committees to wonder how the 
questions should be interpreted.  These interpretations led the committees to change the FDA 
questions or to create new questions before voting. Only two-thirds of all questions were 
answered as worded by the FDA.    
 No research has been specifically conducted in regard to the graphical display of 
quantitative information at FDA advisory committee meetings.  The data presentation that is 
available is limited here in that it is not specific to graphical displays that are projected or 
used as visual aids while a presenter is speaking.  Research most valuable as to how to 
present slides at advisory committee meetings would regard (1) effective graphical displays 
(2) of quantitative information (3) that is viewed via projection (4) while a presenter is 
speaking (5) for the audience to use in a risk/benefit analysis.  
Summary  
 As the previous section demonstrates, FDA advisory committee meetings provide an 
opportunity for the FDA to obtain independent advice about drug safety and effectiveness.  
Effective communication on the part of the FDA and drug sponsors is crucial at these 
meetings. Committees deliver advice at the very meetings where they hear material presented 
for the first time.  Quantitative, clinical trial trail data, in particular, must be presented 
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clearly.  It is the data from clinical trials and real-world experience that drive decisions about 
drug safety and effectiveness.  The tables versus graphs literature—which focuses on 
cognitive fit, perception, and dual-coding theory—provides a framework within which to 
consider how data should be displayed at FDA drug advisory committee meetings.  More 
research into communication practices at advisory committee meetings is needed because of 
a void of research into how data are displayed at these meetings.  The first step to learning 
how data should be displayed must be determining how data currently are displayed.   
Specifically, the research questions that follow are posited. 
  
 
Research Questions 
RQ1:   What types of data presentation formats are prevalent in sponsor and FDA slides 
 shown at U.S. FDA drug advisory committee meetings? 
 
RQ2:  Are there differences in data presentation formats based on: 
 
 RQ2a)  the presenter of the slides (FDA or drug sponsor)?   
 
 RQ2b)  the type of committee? 
 
 RQ2c)  the purpose of the meeting? (i.e. new drug applications,  
  drug withdrawals/safety issues, and request for general advice?) 
  
 
Method 
 A content analysis was conducted to answer the research questions.  The study 
considered all core slides presented at FDA drug advisory committee meetings in 2010 by 
either sponsors or the FDA.  Slides were coded for two variables: slide type and graph type.   
Sample  
 There are sixteen different drug advisory committees.  They are the:  
 Anesthetic and Life Support Drugs Advisory Committee,  
 Anti-Infective Drugs Advisory Committee,  
 Antiviral Drugs Advisory Committee, 
 Arthritis Advisory Committee, 
 Cardiovascular and Renal Drugs Advisory Committee,  
 Dermatologic and Ophthalmic Drugs Advisory Committee,  
 Drug Safety and Risk Management Advisory Committee,  
 Endocrinologic and Metabolic Drugs Advisory Committee,  
 Gastrointestinal Drugs Advisory Committee, 
 Nonprescription Drugs Advisory Committee, 
 Oncologic Drugs Advisory Committee,  
 Peripheral and Central Nervous System Drugs Advisory Committee,  
 Pharmaceutical Science and Clinical Pharmacology Advisory Committee,  
 Psychopharmacologic Drugs Advisory Committee,  
 Pulmonary-Allergy Drugs Advisory Committee, and the 
 Reproductive Health Drugs Advisory Committee. 
 
The sample included all slides that were shown to these committees in 2010 by either drug 
sponsors or the FDA, with the following exceptions: slides that were not yet posted to the 
FDA website as of January 3, 2011, slides shown during the question-and-answer portion of 
the meeting (i.e., backup slides), and slides that were shown to the Pharmaceutical Science 
and Clinical Pharmacology Advisory Committee.  Slides shown to that committee were 
excluded because it has a different function than the other committees do (U.S. FDA, 2010a).  
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 There were no slides posted as of January 3, 2011 for the following committees: 
Antiviral Drugs, Arthritis, Dermatologic and Ophthalmic Drugs, and Nonprescription Drugs.  
Meetings held jointly by two committees were categorized as joint meetings.  As such, 12 
types of committees held a total of 38 meetings in 2010 for which presentations were 
available for analysis.  This yielded a final sample of 86 presentations (38 by the FDA and 48 
by sponsors
4
) and 7,422 slides.  Presentations on average lasted for 70 minutes and included 
86 slides; additional detail is provided in Table 3.  The unit of analysis for this research is the 
individual slide.   
Table 3   
Length of Presentations 
 Overall FDA Sponsors 
Length of presentations  
(mean) 
70 minutes 74 minutes 67 minutes 
Length of presentations  
(range) 
10175 minutes 10175 minutes 10105 minutes 
Slides per presentation  
(mean) 
86 92 82 
Slides per presentation  
(range) 
10330a 20330a 10144 
a
The next-longest presentation consisted of 162 slides. 
 
                                               
4 There were more sponsor presentations than FDA presentations in the sample.  At some advisory committee 
meetings, such as those held to evaluate a class of drugs, the FDA gave one presentation while several sponsors 
presented.  Other variables, such as whether or not the FDA had posted all 2010 presentations at the time the 
sample was taken, also account for the difference in number of FDA and sponsor presentations.  Details of the 
sample, including how many presentations were made at each meeting, are available in Appendix A.  
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Availability of Materials  
 Materials presented at advisory committees are readily available for analysis because, 
by law, the FDA must make them available to the public.  Meeting announcements, slides, 
questions posed to committees, meeting agendas, transcripts, and more are posted to the FDA 
website, http://www.fda.gov/.  Each committee has a page on the site where its materials are 
posted.  The slides used in the sample were downloaded from the committee pages on 
January 3, 2011. 
 
 
Figure 2. EMDAC Page From fda.gov   
 
 
Figure 2.  Each drug advisory committee has a page on the FDA website, similar to the 
EMDAC page shown here, where meeting materials were accessed. 
 
Initial Coding 
 The researcher assigned a unique code to each presentation in the sample and coded 
each for (a) presenter (either sponsor or FDA), (b) committee, (c) meeting purpose, (d) 
number of slides in the presentation, and (e) length of presentation.  Three coding categories 
were established for meeting purpose: new drug application, withdrawal/safety issue, and 
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general advice.  The category for each presentation was determined through a review of the 
FDA‘s formal meeting announcement.  
Content Categories  
 Coding was conducted for two variables: slide type and graph type.  Seven categories 
were established for slide type: text, diagram,/picture, table, graph, table+graph, build, and 
other.  Sixteen categories were established for graph type: bar graph (2D, horizontal), bar 
graph (2D, vertical), bar graph (3D, horizontal), bar graph (3D, vertical),  
stacked bar graph (2D, vertical), stacked bar graph (3D, vertical), line graph, Kaplan-Meier 
curve, pie chart (2D), pie chart (3D), pictograph, forest plot, XY scatter plot, multiple graphs 
(same type) , multiple graph (mixed types), and other.  Categories were established based on 
a qualitative review of slides shown in 2009 at FDA advisory committee meetings, the 
researcher‘s experience,5 and the graph types investigated in the literature reviewed above.   
 Slide type was determined according to the content of the body of the slide, exclusive 
of slide title, background, and background graphics.  The definitions of the seven categories 
for slide type are:  
 Text  
o Text slides contain only text, contain text as the primary focus with 
diagram(s) or picture(s) serving as secondary visuals, or contain text and 
diagrams/pictures in approximately a 50/50 ratio. 
 Diagram  
o Diagram slides contain diagrams or pictures as the primary focal point of the 
slide.  Although they may contain a lot of text, a schematic is clearly being 
used to convey an idea(s). 
  
                                               
5 The researcher developed advisory committee presentations for sponsors from 2005-2008. 
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 Table  
o Table slides contain tables—―a systematic arrangement of data usually in 
rows and columns‖6—either with or without accompanying text.  Slides that 
show text and/or bullets in tabular format were excluded from this category; 
those slides will be coded as diagram/picture slides (an example is shown in 
Figure 2).  If the information displayed in the table could not have been 
displayed in graphical format, the slide is not a table slide   Only slides that 
show data in table format meet the definition of a table slide.   
 
 Graph 
o Graph slides contain graphs—diagrams ―that represent the variation of a 
variable in comparison with that of one or more other variables‖7—either with 
or without accompanying text.   
 
 Table+graph  
o Table+graph slides contain both a table(s) and a graph(s). 
 Build  
o Build slides are nearly identical slides shown in a sequence.  Slides are often 
shown in such a series to emphasize or call attention to specific data.  It would 
be inappropriate to code each slide in the series as a separate slide, as the 
series is usually perceived as one slide by the audience.  Every slide in this 
type of sequence will be coded as a ―build‖ slide except the final slide, which 
will be categorized appropriately.  Note that this will require the coder(s) to go 
backwards and re-code slides as he or she moves to the next slide and realizes 
the build nature of the sequence. 
 
 Other  
o Slides that do not fall into any of the categories above. 
Examples of all of the categories for slide type are included in Appendix B.   
  
                                               
6 http://www.merriam-webster.com/dictionary/table 
7 http://www.merriam-webster.com/dictionary/graph 
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Figure 3. Example of Text and/or Bullets in Table Form   
 
Figure 3. Slides similar to the one shown here were coded as diagram/picture slides.  
This slide does not meet the operational definition of table.  While it does include  
numbers, it does not display quantitative data (Orexigen Therapeutics, 2010). 
 
 
Figure 4. Example of a Build Sequence 
 
Figure 4. These slides, identical with the exception of the third pair of bars, were shown 
sequentially (as indicated by the slide numbers and positions in the file).  When viewed 
full-size on-screen, the build nature of these slides is readily apparent.  In this example, 
slide C40 would be coded as a build slide and slide C41 would be coded as a graph slide 
(Orexigen Therapeutics, 2010). 
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 As slides were coded for type, slides that fell into the graph or table+graph category 
were also coded for graph type.  The definitions of the 16 categories for graph type are:  
 Bar graph (2D, horizontal),  
o A graph that uses the comparative length of rectangles, ovals, or some other 
shape to indicate the size of variables.  The shapes are displayed next to each 
other in a column along the Y axis and may or may not be adjacent.  The 
shapes are displayed horizontally and in two dimensions. Bars may or may 
include error bars; 
 
 Bar graph (2D, vertical),  
o A graph that uses the comparative length of rectangles, ovals, or some other 
shape to indicate the size of variables.  The shapes are displayed next to each 
other in a row along the X axis and may or may not be adjacent.  The shapes 
are displayed vertically and in two dimensions. Bars may or may include  
error bars; 
 
 Bar graph (3D, horizontal),  
o A graph that uses the comparative length of rectangles, ovals, or some other 
shape to indicate the size of variables.  The shapes are displayed next to each 
other in a column along the Y axis and may or may not be adjacent.  The 
shapes are displayed horizontally and in three dimensions; 
 
 Bar graph (3D, vertical),  
o A graph that uses the comparative length of rectangles, ovals, or some other 
shape to indicate the size of variables.  The shapes are displayed next to each 
other in a row along the X axis and may or may not be adjacent.  The shapes 
are displayed vertically and in three dimensions; 
 
 Stacked bar graph (2D, vertical), 
o A graph that uses the comparative length of rectangles, ovals, or some other 
shape to indicate the size of variables.  The shapes are placed on top of each 
other in a continuous stack. The stack is displayed vertically and in two 
dimensions; 
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 Stacked bar graph (3D, vertical), 
o A graph that uses the comparative length of rectangles, ovals, or some other 
shape to indicate the size of variables.  The shapes are placed on top of each 
other in a continuous stack. The stack is displayed vertically and in three 
dimensions; 
 
 Line graph,  
o A graph that plots data points along one axis.  The data points are connected 
by a line. Data points may or may not include error bars; 
 
 Kaplan-Meier curve,  
o A statistical graph that plots the estimated amount of time it takes for a 
particular event to occur (time to event).
8
  These graphs are recognizable by 
the stair-like progression of the plot lines; 
 
 Pie chart (2D), 
o A chart that consists of a circle divided into two or more sections by radii of 
the circle.  The size of the sections indicates the size of the variables they 
represent.  The sections may or may not be pulled out from the ―pie‖ as a 
whole.  The sections of the pie are represented in two dimensions; 
 
 Pie chart (3D),  
o A chart that consists of a circle divided into two or more sections by radii of 
the circle.  The size of the sections indicates the size of the variables they 
represent.  The sections may or may not be pulled out from the ―pie‖ as a 
whole.  The sections of the pie are represented in three dimensions; 
 
 Pictograph,  
o A graph that displays geometric or human-shaped icons in relation to other 
icons to indicate the size of the variable(s) they represent; 
 
 Forest plot, 
o A graph that plots data points and their confidence intervals along one axis.  
The data points are usually plotted along a horizontal axis and stacked in a 
column, however, they may also be plotted along a vertical axis and appear in 
a row;  
 
                                               
8 http://faculty.chass.ncsu.edu/garson/PA765/kaplanmeier.htm 
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 XY scatter plot,  
o A graph that displays data points plotted along both an X and Y axis.  The 
graph may or may not include a line of regression; 
 
 Multiple graph, same type (specify),  
o A slide that shows two or more graphs of the same type; 
 Multiple-graph, mixed types (specify),  
o A slide that shows two or more graphs of different types; 
 Other,   
o Graph slides that do not fall into any of the categories above.  These slides 
will be recoded if additional graph categories emerge during the first round  
of coding. 
 
Examples of each graph type are included in Appendix B.   
Coding 
 Approximately half of the sample (43 presentations, 3, 975 slides) was coded by the 
researcher, the rest of the sample (43 presentations, 3,477 slides) was coded by a volunteer 
coder.  In order to assign presentations to either the researcher or the coder, the presentations 
were listed in alphabetical order by committee name.  Every other FDA presentation on the 
list was assigned to either the researcher or the coder, as was every other sponsor 
presentation.  The group that included presentation F14 was assigned to the coder because 
the researcher helped create that presentation as a consultant to the sponsor.   
Coder Training  
 Prior to coding, the coder received (a) instructions, (b) a quick-reference list of slide 
types/graph types, and (c) definitions and example(s) of each category.  Copies of these 
training materials can be found in Appendix B.      
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 Initial training consisted of a review of the coding instructions and category 
definitions.  The coder then practiced coding two presentations that had been shown at 
advisory committee meeting in 2009.  This coding was done orally, and miscodes were 
discussed as they occurred.  Fourteen of 244 practice slides were miscoded.  Almost all of the 
miscodes, 13, involved table or diagram slides.  Therefore, a third presentation was spot-
coded for those two slide types.  A second training session was held at a later date to further 
assure the coder‘s ability to distinguish between table and diagram slides. 
Intercoder Reliability Sample and Testing   
 In order to conduct tests for intercoder reliability, a random sample of the slides 
assigned to the coder (stratified by type of committee) was also coded by the researcher. A 
random number (20) was obtained from random.org.  The presentations assigned to the 
volunteer coder were listed in alphabetical order by committee name and then by 
presentation code.  Every 20th FDA presentation and every 20th sponsor presentation to each 
committee was selected for the intercoder reliability sample.  There were 19 presentations 
and 1,476 slides in the intercoder reliability sample.  This is 22.09% of the total sample of 
presentations and 19.89% of the total sample of slides. 
 Initial tests for intercoder reliability, calculated using Hayes‘ 2007 macro for 
Krippendorff‘s alpha, revealed an  of 0.8172 for slide type and 0.8410 for graph type. 
Despite this acceptable level of reliability, two additional training sessions were held to 
further ensure the coder could categorize slides/graphs appropriately.  At these training 
sessions, all disagreements that occurred in the intercoder reliability sample were reviewed 
and discussed. 
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Coding Procedures   
 The coder received a memory stick with copies of all of the presentations to be coded.   
The presentations were in PDF format, which is how the FDA provides the files.  Each file 
that had been downloaded from the FDA website was renamed with a unique code assigned 
by the researcher, for example, F16.pdf or S24.pdf.  The coder also received a spreadsheet 
that listed (1) the unique file code for each presentation, (2) committee, (3) whether the 
presentation was an FDA or sponsor presentation, and (4) number of core slides in the 
presentation.  
 Slides were coded via online coding instrument.  One coding instrument was 
completed for each presentation in the sample. Presentations were viewed in full-screen 
mode on a computer screen during coding.      
 The first six questions in the code sheet required the coder/researcher to enter 
information from the provided spreadsheet.  Those questions are shown in Figure 5 below.  
Figure 5. Initial code sheet questions 
.  
 The primary code sheet question was ―Is slide 1 a. . .,‖ with the choices being the 
seven slide type categories.  Only one response per question was allowed, and that 
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response was required in order to proceed to the next question.  If the coder/researcher 
chose text, diagram, table, build, or other, the coding instrument proceeded to the next 
question, which inquired about slide 2, etc.  If the coder/researcher identified any slide as a 
graph or table+graph, the next question inquired as to what to of graph it was, with the 
choices being the sixteen graph types.  If the slide contained multiple graphs, same type or 
multiple graphs, mixed types,  the coder/researcher was required to specify the graph 
type(s) in a text box.  The coder/researcher then proceeded to the slide type question for 
the next slide in the presentation. 
 Figure 6. Primary code sheet questions 
 
 
  
 
Results 
 A final sample of 7, 422 slides (86 presentations) was coded for slide type and, when 
applicable, graph type.  The results are reported overall, by FDA/sponsor, by committee, and 
by meeting purpose. 
Research Question 1: Prevalence of Data Presentation Formats 
 Text slides dominated the sample at 57.65% of the overall slides, as indicated in 
Table 4.  In fact, the non-data slides, which, in addition to text slides, included 
diagram/picture slides, build, and other slides—comprised 69.93% of the slides shown at 
advisory committee meetings in 2010.  
Table 4  
Slides by Type (Overall) 
 
Total 
N=7,422 
n (%) 
Text 4,279 (57.65) 
Diagram/picture 761 (10.25) 
Table 1,008 (13.58) 
Graph 1,099 (14.81) 
Table+Graph 125 (1.68) 
Build 136 (1.83) 
Other 14 (0.19) 
 
 The 30.07% of the sample that represents data slides—that is table, graph, or 
table+graph slides—are the slides of interest here, because those are the slides that speak to 
the research questions of how data are presented.  The data slides are detailed in Table 4.  Of 
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the data slides, table slides and graph slides were seen almost equally across the sample, at 
45.16% and 49.23%, respectively.  Slides that used tables and graphs in combination were 
rare, less than 2% of the slides overall (as shown in Table 3) and only 5.6% of the data slides 
(as shown in Table 5). 
Table 5 
 
Data Slides by Type (Overall) 
 
Total 
N=7,422 
n (%) 
Non-data slides 5,190 (69.93) 
Data slides 2,232 (30.07) 
Table 1,008 (45.16) 
Graph 1,099 (49.23) 
Table+Graph 125 (5.6) 
  
 There were 1, 224 slides in the sample that featured graphs—that is, graph slides or 
table+graph slides.  Those slides were subcategorized into one of sixteen categories, for 
example, line graph or Kaplan-Meier curve, according to graph type.   
 With only 1,224 slides displaying graphs, the graph types were quite spread out 
across the sixteen categories (detailed in Table 6).  Some categories held as few as 0% to 2% 
of the graphs.  For this reason, some categories with smaller slide counts were collapsed into 
others before further analysis.  Specifically, the first six categories—which represented some 
form of bar graph—were collapsed into the new category all bar graphs, the two types of pie 
charts were collapsed into all pie charts, and XY scatter plots were folded into the other 
category.  The multiple graph, same type category was eliminated, and those slides were 
redistributed into the appropriate graph type category.  For example, 27 of the 179 slides 
initially coded into the multiple graph, same type category displayed more than one line 
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graph.  This was evident because coders were required to specify, by way of a text box, the 
type of graph displayed on multiple graph slides.  Those 27 slides were recoded as line 
graphs; other graphs in the multiple graph, same type category were similarly recoded, and 
the category was eliminated.  
Table 6 
Original Distribution of Graphs by Type (Overall) 
  
Total 
N=1,224 
n (%) 
Bar graph (2D, horizontal) 21 (1.72) 
Bar graph (2D, vertical) 288 (23.53) 
Bar graph (3D, horizontal) 1 (0.08) 
Bar graph (3D, vertical) 14 (1.14) 
Stacked bar graph (2D, vertical) 23 (1.88) 
Stacked bar graph (3D, vertical) 1 (0.08) 
Line graph 200 (16.34) 
Kaplan-Meier curve 143 (11.68) 
Pie chart (2D) 20 (1.63) 
Pie chart (3D) 7 (0.57) 
Pictograph 0 (0) 
Forest plot 189 (15.44) 
XY scatter plot 12 (0.98) 
Multiple graph, same type (specify) 179 (14.62) 
Multiple graph, mixed types (specify) 31 (2.53) 
Other 95 (7.76) 
 
  After revisions, there were eight graph categories, shown in Table 7, instead of 
sixteen.  The most prevalent formats seen were all bar graphs, (33.17%), forest plots 
(18.63%), line graphs (18.55%), and Kaplan-Meier curves (14.05%).  Together, these four 
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graph types account for 84.40% of all graph usage.  Only one slide in the entire sample, 
shown by a sponsor at a psychopharmacologic drugs meeting, used a pictograph.  
Table 7 
Graphs by Type (Overall) 
 
Total 
N=1,224 
n (%) 
All bar graphs
a
 406 (33.17) 
Line graph 227 (18.55) 
Kaplan-Meier curve 172 (14.05) 
All pie charts
b
 39 (3.19) 
Pictograph 1 (0.08) 
Forest plot 228 (18.63) 
Multiple graphs, mixed types 31 (2.53) 
Other
c
 120 (9.8) 
a
All bar graphs includes: bar graphs (2D, horizontal), bar graphs (2D, vertical), bar graphs 
(3D, horizontal), bar graphs (3D, vertical), stacked bar graphs (2D, vertical) and stacked bar 
graphs (3D, vertical). 
b
All pie charts includes: pie charts (2D), and pie charts (3D). 
c
Other includes: XY scatter plots and other. 
 
 
 Figure 7. Pictograph 
 
Figure 7.  This slide, shown by drug sponsor Alkermes, Inc at a Psychopharmacologic 
Drugs Advisory Committee meeting in September 2010, was the only pictograph shown to 
a drug advisory committee by a sponsor in 2010 (Alkermes, Inc., 2010).  The FDA showed 
no pictographs.  
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Research Question 2a: Results by Presenter (FDA/Sponsor)  
 Of the 7,422 slides in the sample, 3,508 were shown by the FDA and 3,914 were 
shown by drug sponsors. The breakdown of these slides by type is shown in Table 8.  The 
FDA was much more likely than sponsors to show data in tables versus graphs—50.96% of 
the FDA‘s data slides were tables, as opposed to 40.97% of sponsors‘. 
Table 8  
Data Slides by Type (by FDA/Sponsor) 
 
FDA 
N=3,508 
n (%) 
Sponsor 
N=3,914 
n (%) 
Non-data slides 2,572 (73.32) 2,618 (66.89) 
Data slides 936 (26.68) 1,296 (33.11) 
Table 477 (50.96) 531 (40.97) 
Graph 427 (45.62) 672 (51.85) 
Table+Graph 32 (3.42) 93 (7.18) 
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 Graph type usage was very similar between the FDA and sponsors.  Both groups were 
more likely to use bar graphs than any other format and least likely to use pie charts or 
pictographs.  Seven of the eight graph types were utilized by both the FDA and sponsors, and 
the proportion of graph use by type was similar between the two groups. 
 
Figure 8 
Graphs by Type (by FDA/Sponsor) 
 
aAll bar graphs includes: bar graphs (2D, horizontal), bar graphs (2D, vertical), bar graphs (3D, horizontal), 
bar graphs (3D, vertical), stacked bar graphs (2D, vertical) and stacked bar graphs (3D, vertical). 
bAll pie charts includes: pie charts (2D), and pie charts (3D). 
cOther includes: XY scatter plots and other. 
 
Research Question 2b: Results by Committee  
As Figure 9 shows, a broad range of data slide usage was found across committees.  
The largest difference occurred during Drug Safety and Risk Management Committee 
meetings, where the difference in percent of data shown via graph versus table was 59%.  
The smallest difference occurred with the Reproductive Health Drugs Advisory Committee, 
which saw a 6% difference in data slide types.  Six committees saw more table slides than 
graph slides, five saw more graph slides than table slides, and one saw an equal split of the 
two types of slides.   
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The only committee for which a substantial portion of data was presented via 
table+graph slides was the Cardiorenal Drugs Advisory Committee.  Fourteen percent of the 
data slides shown to that committee utilized both tables and graphs in combination. The next 
highest percentage was eight, with all other committees seeing 0% to 5% of data slides in the 
table+graph combination.  
A broad range of graph types, too, was seen across committees.  Graph use is 
displayed in Figure 10.  The bar graph was the most-common graph used at nine out of 
twelve committees, though its use ranged from 22% (at cardiorenal meetings) to 60% (at 
peripheral and central nervous system meetings) of the graphs overall.  That format‘s lower 
usage at cardiorenal meetings drove that committee to see a more even distribution of graphs 
than other committees did.  The reproductive health committee saw the least variation, with 
only three types of graphs used: bar graphs, line graphs, and forest plots.  Only one 
committee saw any pictographs, and only half of the committees saw all seven of the other 
graph types.   
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Figure 9 
Data Slides by Type (by Committee) 
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Figure 10 
Graphs by Type (by Committee) 
 
aAll bar graphs includes: bar graphs (2D, horizontal), bar graphs (2D, vertical), bar graphs (3D, horizontal), bar 
graphs (3D, vertical), stacked bar graphs (2D, vertical) and stacked bar graphs (3D, vertical). 
bAll pie charts includes: pie charts (2D), and pie charts (3D). 
cOther includes: XY scatter plots and other. 
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Research Question 2c: Results by Meeting Purpose  
 As there was across committees, there was a large difference in data slide type use 
across meeting purposes, shown in Table 9.  Slides that displayed tables and graphs in 
combination were, again, used rarely and in approximately equal measure across groups.  
Tables and graphs were presented in nearly equal measure at meetings held to consider New 
Drug Applications (at 47.59% and 46.49% of the data slides, respectively).  However, there 
was a 19% difference between table slide use (37.8%) and graph slide use (56.84%) at 
withdrawal/safety issue meetings, and 17% difference (39.55% and 56.82%) at general 
advice meetings.   
Table 9 
Data Slides by Type (by Meeting Purpose) 
 
NDA 
N=4,832 
n (%) 
Withdrawal/ 
Safety Issue 
N=1,230 
n (%) 
General 
Advice 
N=1,360 
n (%) 
Non-Data slides 3,193 (66.08) 857 (69.67) 1,140 (83.82) 
Data slides 1,639 (33.92) 373 (30.33) 220 (16.18) 
Table 780 (47.59) 141 (37.8) 87 (39.55) 
Graph 762 (46.49) 212 (56.84) 125 (56.82) 
Table+Graph 97 (5.92) 20 (5.36) 8 (3.64) 
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 In terms of graph types across meeting purposes, NDA meetings saw more bar graphs 
(38.07%) than any other type of graph, followed by forest plots, line graphs, and Kaplan-
Meier curves, each at about 15% of the overall graphs.  These same four graph types were 
the most common at withdrawal/safety issue meetings, at which each of the four graph types 
represented about 20% of the total.  So, withdrawal/safety issue meetings see the same types 
of graphs as NDA meetings and in a similar makeup, just with slightly fewer bar graphs.  
Three of the same formats—bar graphs, line graphs, and forest plots—were also prevalent at 
general advice meetings.  Kaplan-Meier curve usage, however, was drastically reduced at 
these meetings compared to those held for other purposes, at only 5.26% of the overall 
graphs.  Instead, ―other‖ graphs are the fourth-most-common graph type at general meetings, 
at a full 16.54 % of overall graphs.    
 
Figure 11 
Graphs by Type (by Meeting Purpose) 
 
a
All bar graphs includes: bar graphs (2D, horizontal), bar graphs (2D, vertical), bar graphs (3D, horizontal), 
bar graphs (3D, vertical), stacked bar graphs (2D, vertical) and stacked bar graphs (3D, vertical). 
bAll pie charts includes: pie charts (2D), and pie charts (3D). 
cOther includes: XY scatter plots and other.
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Discussion and Conclusions 
 This research sought to understand how data are presented at FDA drug advisory 
committee meetings.  Two primary data displays were investigated—tables versus graphs.  
The prevalence of different graph types was also investigated.  As the results showed, there 
were both similarities and differences across groups in how data were displayed.     
Tables versus Graphs 
  Overall, about half of the data presented at FDA drug advisory committee meetings 
are presented in tables and about half are presented in graphs. The prevalence of both tables 
and graphs seems to indicate that presenters at advisory committee meetings want to convey 
verbatim information and gist information in equal measure.  The table+graph combination, 
studied in the interest of both (a) having mutually slide categories and (b) interest in whether 
presenters combine the best format for verbatim information (tables) with the best format for 
gist information (graphs), was used rarely.   
Tables and graphs were found almost equally across the sample.  However, the FDA 
is much more likely to display data in tables versus graphs than sponsors are— 51% of the 
agency‘s data slides were tables, as opposed to 41% of sponsors‘.  While reasons as to this 
difference are speculative, they may indicate a preference on the part of the FDA for 
communicating verbatim information versus conclusions (gist information) about the data.  
Or, the reasons may result from the fact that sponsors are in a position to hire outside slide 
developers for advisory committee meeting preparation, while the FDA is not.  Such vendors 
specialize in the use of software programs typically employed to make slides, such as 
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Microsoft PowerPoint, and may have more expertise in graph construction than the FDA 
does.  
   About half of the committees saw more data in tables than in graphs in 2010.  There 
was a broad range among committees in the proportion of slides that utilized each format.  
Graphs dominate at drug safety and risk management committee meetings (80.49% graphs) 
and at joint meetings (60.08% graphs). Meanwhile, the six committees that saw more tables 
than graphs saw them in a narrower proportion, with a range of 6%-17% more table slides 
than graph slides. These observations indicate that there are differences in how data are 
presented at each committee.   
 Not surprisingly, data slides overall were much less common at meetings held to 
obtain general advice from committees than at meetings held to discuss new drug 
applications or drug safety issues.  Data slides only account for 16.18% of all slides shown at 
general advice meetings, as opposed to 33.92% and 30.33% at NDA and withdrawal/safety 
issue meetings. This makes sense, because decisions at NDA and withdrawal/safety issue 
meetings are data-driven, while decisions at general advice meetings may not necessarily be.  
If the FDA is seeking advice from a committee about appropriate study designs (as was the 
case with the joint pulmonary allergy/DSaRM meeting on March 10, 2010), for example, 
there may be little clinical data to share.  The focus of those presentations would not on the 
results of drug trials or on data collected from real-world drug use, but on elements of study 
design and potential endpoints, issues that would not call for the presentation of data. 
 There is a substantial difference in the way data are presented based on meeting 
purpose.  Table slides and graph slides were used in approximately a 50/50 ratio at meetings 
held to discuss new drug applications.  This is in striking contrast to meetings held for any 
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other purpose, where about approximately 20% more data slides were graphs versus tables.  
This disproportion seems to indicate more of an interest in presenting verbatim information 
at NDA meetings than at meetings held for any other purpose.   
Graph Type 
 Graph use overall was dominated by the four most-prevalent types of graphs: all bar 
graphs, forest plots, line graphs, and Kaplan-Meier curves.  Each of these graph types 
typically serves a mutually exclusive purpose; for example, bar graphs are used to display 
parts of a whole (Cleveland & McGill, 1984) and line graphs are used to display data in a 
time series (Reynolds, 2010).  Pie charts and bar graphs, in contrast, do not serve mutually 
exclusive purposes.  Both are often used to show parts of a whole (Cleveland & McGill, 
1984).  The exclusivity of the graph types that were prevalent in the sample would seem to 
indicate that each of the common graph types is commonly accepted/preferred over others for 
its particular function by presenters in this environment.   
 The collapse of the original sixteen graph categories into eight was necessary to see 
any real similarities or differences in graph types across groups (particularly committees).  
What was lost due to the collapse was the opportunity to explore more-refined graph options, 
such as 2D versus 3D bar graphs.  Nevertheless, the sample was not large enough for this 
exploration.  
The findings regarding graphs do beg the question of why pictographs are not used 
more commonly in the advisory committee setting.  Tait et al. (2010) make a strong case for 
the format, finding pictographs to be better than text or tables at conveying both gist and 
verbatim information, even in high numeracy individuals.  Participants in the Tait et al. study 
also rated pictographs as more effective, helpful, scientific, and trustworthy than text or 
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tabular formats.  One cause for the format‘s absence might be the fact that pictographs are 
not a built-in graph option in standard slide development software programs.  However, that 
is also the case with Kaplan-Meier curves, which made up 14.05% of the graphs in the 
sample.  Further exploration of this question is warranted.  Are Kaplan Meier curves easily 
produced in statistical software, and thus find their way onto slides more easily than 
pictographs do?  Are other factors, such as a perception within the pharmaceutical 
community that pictographs are unscientific, causing the format to be overlooked?  Or, is 
simple lack of awareness of the utility of the pictograph driving its absence from advisory 
committee presentations? 
 The distribution of graph types by presenter—FDA versus sponsor—was strikingly 
similar.  The largest difference was only 8%, seen with bar graphs, with sponsors being more 
likely to use that format than the FDA was.  So, while differences in graph type usage 
between the FDA and sponsors were evident, they were not pronounced.  This similarity in 
graph choice seems to indicate that the factors that drive decisions regarding graph type are 
similar for both sets of presenters.  The data themselves, and not other, external factors, are 
the most likely candidate.   
There were similarities and differences in graph type use between committees.  The 
four most common graphs overall were all seen by 11 of the 12 committees.  Some 
committees (GDAC, Perip. & Cent. Nerv. Sys., Pul. Allergy, and Reproductive Health) saw 
no pie charts, while that format constituted a full 12.12% of graphs shown to the DSaRM 
committee.  Because graph type did not vary much across presenters (FDA/sponsors) or 
across meeting purposes, it is possible that the difference here are driven by the small n‘s.  A 
larger sample would have been useful in evaluating difference across committees further.  
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As with FDA/sponsors, findings for graph type were similar across meeting purposes.   
When data are presented graphically there is little variation in graph format regardless of 
meeting purpose. 
Limitations 
 This research describes how data are presented at FDA drug advisory committee 
meetings.  It does not speak to why data are presented the way they are or suggest how they 
should be presented.  Neither does this research speak to whether choice of format affects the 
decisions made by advisory committee members. 
 Slides are only one part of overall communications at advisory committee meetings.  
This research considered only data presentation formats, and considered them in the absence 
of other things that may affect their effectiveness.  The oral presentation that accompanies 
the slides and the lengthy briefing documents that committee members receive in advance of 
a meeting likely impact committee members‘ understanding of the data.  The research 
presented here did not evaluate data presentation formats in the context of these other 
elements of communication. 
Finally, as previously stated, the sample size here did not allow for additional 
distinctions in graph use across groups, such as the use of 3D graphs versus 2D graphs.  
These and explorations of other factors that impact graph effectiveness, such as extraneous 
information, color, and labels, were not conducted. 
Conclusions 
The utility of this research lies in its ability to provide a baseline understanding of 
how quantitative data are communicated at drug advisory committee meetings.  To the 
researcher‘s knowledge, communication practices at these meetings have never been 
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investigated via an academic rubric.  The research led to three key findings; one of which 
was general and two of which were in regard to how the FDA communicates compared to 
drug sponsors.  We now know that (1) tables and graphs are used in nearly equal measure at 
advisory committee meetings, (2) that the FDA is more likely than drug sponsors to display 
data in tables versus graphs, and (3) that graph types are used in strikingly similar 
proportions by the FDA and sponsors.    
What are the implications of these findings?  The literature, though inconclusive, 
suggests that tables are the most effective format for the presentation of verbatim information 
and graphs are the most effective format for the presentation of gist information (Smerecnik 
et al., 2010).  Since both formats are used in equal measure at advisory committee meetings, 
it is safe to conclude that presenters in this arena give weight to both types of information.  
They want committee members to have access both to specific data values—verbatim 
information, and to data that offer comparisons—most likely of the sponsor‘s drug to a 
placebo or the standard of care.   
That the FDA is more likely to use tables than graphs may mean that the agency‘s 
focus is on providing verbatim data to committee members.  Sponsors, on the other hand, 
may be more interested in communicating conclusions about the data than the verbatim 
values.  This dichotomy makes sense and may even be beneficial to the drug approval 
process; after all, sponsors are more familiar with their data than other advisory committee 
participants and may be in the best position to draw conclusions.  The FDA, on the other 
hand, does not want to impart their conclusions to a committee as much as garner the 
committee’s opinion about the data.  Committee members, thus, become privy to verbatim 
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information via the FDA and gist information via sponsors.  Both types of information are 
necessary to weigh medical benefit/risk information—the very act the committee engages in.  
The research presented here informs how groups communicate at advisory committee 
meetings.  However, without further research, it is impossible to know if they communicate 
in the most-effective manner.  Remember, information is communicated effectively if the 
audience receives, comprehends, agrees with, retains, and retrieves it (McGuire, 1976).  
When it comes to the communication of quantitative information, effectiveness may hinge 
upon the format used to display the data.  The oral nature of advisory committee 
presentations, however, must be taken into account when determining the effectiveness of 
data display formats.   
Dual-coding theory suggests that tables, with their inherent verbal nature, may not be 
the best format for communicating verbatim information during an oral presentation.  
Remember, dual-coding theory holds that verbal information—information that requires 
language to be comprehended—should not be delivered over auditory and visual channels at 
the same time (Doumont, 2002; Paivio, 1991; Tait, 2010).  Are committee members too 
focused on the verbal speech to make sense of the verbal information presented in a table?  
Are they too focused on the table to make sense of the speech?  In other words, are advisory 
committee presenters lowering the effectiveness of their communications when they use 
tables by delivering competing information simultaneously?  If dual-coding theory holds 
true, they are.  The data would be delivered more effectively if displayed in a format that was 
more non-verbal in nature, like a graph. 
Only through additional research will questions of effectiveness be answered.  
Research designs that take cognitive fit and dual-coding theory, at a minimum, into account 
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are a necessary first step.  An experiment that would best approximate the conditions at a 
committee meeting would use participants randomized to view medical benefit/risk 
information in a table or graph while they listen to an oral presentation.  A more-refined 
investigation of graphic visuals is also in order.  Color (Mackiewicz, 2007), 2D versus 3D 
formatting (Mackiewicz, 2007; Stewart et al., 2009), gridlines (Tufte, 2001), and labels 
(Tufte, 2001) are all known to affect the effectiveness of graphs.   Are decisions regarding 
these and other formatting choices being made wisely by advisory committee presenters?  A 
determination cannot be made until formatting choices are investigated in an environment 
that approximates the advisory committee setting. 
Until the research outlined above is conducted, the FDA and sponsors can turn to 
theories such as cognitive fit and dual-coding to inform their decisions regarding data 
presentation.  If the presentation format should fit the task, as cognitive fit theory suggests, 
then data that inform spatial tasks should be presented via graphs.  Data that need to be 
communicated verbatim should be presented via tables.  Presenters will thus provide 
information to committee members via a format that will fit with the task the committee will 
undertake.   However, all slides, whether they forward spatial or verbatim thinking, should be 
kept as non-verbal as possible.  The reason for this is that advisory committee slides are 
accompanied by an oral presentation—which is inherently verbal in nature.  Dual-coding 
theory holds that verbal information presented simultaneously via visual and auditory 
channels cannot be processed by the audience.  Speakers, in essence, cancel out their 
communications when both their slides and accompanying speech are verbal.  Slides can be 
kept non-verbal by following commonly purported advice to reduce clutter, use consistent 
scales, and eliminate unnecessary visual elements.  Tables are verbal in nature and may 
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present a challenge—appropriate pausing by speakers to allow committee members to 
process tabular data may be one solution.  Another solution may be to explore use of the 
pictograph in lieu of tables to present verbatim data.  Although, since committee members 
are unaccustomed to seeing pictographs in advisory committee presentations, the FDA and 
sponsors would be wise to first test the format in other arenas or to seek feedback on the 
format from outside medical consultants. 
Lives and livelihoods are on the line at FDA drug advisory committee meetings.  The 
former, for patients who depend upon the availability of safe, effective medications; the later, 
for drug company employees and investors who depend on the financial success of drug 
development.  While advisory committees do not have the final say regarding drug approval, 
their advice plays an influential role.  Those who have the privilege of addressing advisory 
committees, whether they represent the FDA or drug developers, have an obligation to 
represent the data well.   
The understanding of how quantitative data are communicated at drug advisory 
committee meetings gleaned from this research provides a basis for future research. 
Furthermore, it may bring attention to the understudied question of how data are evaluated by 
committees chartered to advise the government about drug safety and effectiveness in the 
United States. 
 
Appendix A 
Details of the Sample 
 Anesthetic and Life Support Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from: 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/AnestheticAndLifeSupportDrugsAdvisoryCommittee/ucm193298.htm 
o 6 meetings listed for 2010 (2 were cancelled) 
o 3 meetings were joint with DSaRM 
o Final sample size of:  
 1 meeting 
 1 FDA presentation 
 1 sponsor presentation 
 
 Anti-Infective Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from: 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/Anti-InfectiveDrugsAdvisoryCommittee/ucm208081.htm 
o 2 meetings listed for 2010 
o Note: at the Sept 7 meeting, the committee considered one drug for two 
indications.  Both the FDA and the Sponsor presented on each indication 
separately. 
o Final sample size of:  
 2 meetings 
 3 FDA presentations 
 3 sponsor presentations 
 
 Antiviral Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/AntiviralDrugsAdvisoryCommittee/ucm206847.htm 
o 1 meeting listed for 2010   
o Note: no slides were posted as of 3 Jan 2011 
o Final sample size of: 
 0 meetings 
 0 FDA presentations 
 0 sponsor presentations 
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 Arthritis Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/ArthritisDrugsAdvisoryCommittee/ucm203434.htm 
o 3 meetings listed for 2010  
o 2 meetings were joint with DSaRM 
o Note: no slides were posted for the 16 Nov meeting as of 3 Jan 2011 
o Final sample size of:  
 0 meetings 
 0 FDA presentations 
 0 sponsor presentations 
 
 Cardiovascular and Renal Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/CardiovascularandRenalDrugsAdvisoryCommittee/ucm192863.htm 
o 7 meetings listed for 2010  
o Note:  at the 8 Dec meeting, there was no FDA presentation.  There was no 
sponsor, but there was a presentation from ―industry‖ that was included in the 
sample. 
o Final sample size of:  
 7 meetings 
 6 FDA presentations 
 7 sponsor presentations 
 
 Dermatologic and Ophthalmic Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/DermatologicandOphthalmicDrugsAdvisoryCommittee/ucm211780.htm 
o 1 meeting listed for 2010 (but it was cancelled) 
o Final sample size of:  
 0 meetings 
 0 FDA presentations 
 0 sponsor presentations 
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 Drug Safety and Risk Management Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/DrugSafetyandRiskManagementAdvisoryCommittee/ucm199874.htm 
o 10 meetings listed for 2010 (one of which was cancelled, 8 of which were 
joint) 
o Note:  at the 14 Sept meeting, there was no sponsor presentation per se.  
CHPA gave a presentation in a role similar to that of a sponsor and that 
presentation was included in the sample. 
o Final sample size of:  
 1 meetings 
 1 FDA presentations 
 1 sponsor presentations 
 
 Endocrinologic and Metabolic Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm191113.htm 
o 7 meetings listed for 2010 (one of which was cancelled, 1 of which was joint) 
o Note: no slides were posted for the 12-13 Jan or 27 May meetings as of 3 Jan 
2011. 
o Final sample size of:  
 3 meetings 
 3 FDA presentations 
 3 sponsor presentations 
 
 Gastrointestinal Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/GastrointestinalDrugsAdvisoryCommittee/ucm195280.htm 
o 3 meetings listed for 2010  
o Note: a ―sponsor presentation‖ is listed on the agenda for the 4 Nov meeting 
and that presentation is included in the sample.  It is not clear from the 
agenda, the meeting announcement, or the slides who the sponsor is.  Based 
on the topic of the meeting and the affiliations of the speakers, it seems that 
this is an ―industry‘ presentation. 
o Note: multiple companies are listed as sponsors for the 5 Nov meeting.  The 
FDA presentation at this meeting was very short, 10 minutes and 26 slides, 
but is included in the sample.  
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o Final sample size of:  
 3 meetings 
 3 FDA presentations 
 3 sponsor presentations 
 
 Nonprescription Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/NonprescriptionDrugsAdvisoryCommittee/default.htm 
o Note: no meeting information at all is posted for 2010 
o Final sample size of:  
 0 meetings 
 0 FDA presentations 
 0 sponsor presentations 
 
 Oncologic Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/OncologicDrugsAdvisoryCommittee/ucm195226.htm 
o 6 meetings listed for 2010 (one of which was postponed, one of which was a 
meeting of the ODAC pediatric subcommittee) 
o Note: The 22 March meeting considered two separate issues.  There were two 
FDA presentations and two sponsor presentations.  
o Note: The 30 Nov meeting included one FDA presentation and 4 separate 
presentations from 4 different sponsors.   
o Note: The 1 Dec meeting considered two separate issues.  There were two 
FDA presentations and two sponsor presentations.  
o Final sample size of:  
 5 meetings 
 7 FDA presentations 
 10 sponsor presentations 
 
 Peripheral and Central Nervous System Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/ucm204899.
htm 
o 4 meetings listed for 2010 (one of which was joint with DSaRM) 
o Note: no FDA presentation was given at the 6 May or 11 Aug meetings. 
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o Final sample size of:  
 3 meetings 
 1 FDA presentation 
 3 sponsor presentations 
 
 Psychopharmacologic Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/PsychopharmacologicDrugsAdvisoryCommittee/ucm221387.htm 
o 1 meeting listed for 2010  
o Final sample size of:  
 1 meeting 
 1 FDA presentation 
 1 sponsor presentation 
 
 Pulmonary-Allergy Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/Pulmonary-AllergyDrugsAdvisoryCommittee/ucm199877.htm 
o 3 meetings listed for 2010 (one of which was joint with DSaRM) 
o Final sample size of:  
 2 meetings 
 2 FDA presentations 
 2 sponsor presentations 
 
 Reproductive Health Drugs Advisory Committee 
o Materials accessed 3 Jan 2011 from:  
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/ReproductiveHealthDrugsAdvisoryCommittee/ucm210869.htm 
o 2 meetings listed for 2010  
o Final sample size of  
 2 meetings 
 2 FDA presentations 
 2 sponsor presentations 
 
 Joint meetings 
o Materials accessed 3 Jan 2011.  All joint meetings were between DSaRM and 
some other committee.  Materials were accessed from the ‗other‘ committee‘s 
page, e.g., materials from joint meetings of DSaRM and CRDAC were 
accessed from the CRDAC page.  
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o Joint DSaRM and Anesthetic and Life Support Drugs Advisory Committee 
 3 joint meetings 
 3 FDA presentations 
 5 sponsor presentations 
o Joint DSaRM and Arthritis Drugs Advisory Committee 
 2 joint meetings 
 2 FDA presentations 
 2 sponsor presentations 
o Joint DSaRM and Peripheral and Central Nervous System Drugs Advisory 
Committee 
 1 joint meetings 
 1 FDA presentation 
 1 sponsor presentations 
o Joint DSaRM and Endocrinologic and Metabolic Drugs Advisory Committee 
 Note: there were two sponsors listed for this meeting, but in one set of 
sponsor slides, there were only two slides.  Furthermore, those slides 
did not appear to constitute a presentations, rather, they looked like 
slides that would appear anywhere in a presentation.  Therefore, that 
presentation was excluded from the sample. 
 1 joint meetings 
 1 FDA presentation 
 1 sponsor presentations 
o Joint DSaRM and Pulmonary-Allergy Drugs Advisory Committee 
 1 joint meetings 
 1 FDA presentation 
 3 sponsor presentations 
o Total sample size for all joint meetings of  
 8 meetings 
 8 FDA presentations 
 12 sponsor presentations 
Appendix B 
Copies of Training Materials 
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Instructions
Thank you for volunteering to code slides for my thesis.  You will be categorizing slides that 
were shown to FDA advisory committees in 2010 by either the FDA or a pharmaceutical 
sponsor. 
The slides are  part of presentations that have been sent to you on  a memory stick.  Other 
resources you will need include these instructions and an Excel spreadsheet that has been 
emailed to you.  
You will code slides into one of seven categories listed on the next page.  You will 
subcategorize slides that fall into either the ‗graph‘ or ‗table+graph‘ categories into one of 16 
subcategories, also listed on the next page. Definitions of each category and subcategory are 
included in these instructions.  In many cases, examples have also been provided.  Take your 
time and remember to ask yourself: ―what is the intent of this slide?‖ as you code.
You will code the slides via online surveys.  The surveys are accessible at: 
https://uncodum.qualtrics.com/SE/?SID=SV_3elF4D2xGQYZuJu.  The surveys require a 
password, which is ‗thesis‘.  Answer one survey for each presentation assigned to you.
The  Excel spreadsheet that was emailed to you lists all of the presentations that you will 
code.  It also includes additional information that you will enter into each survey.  This 
information includes: the survey code (filename), the committee that the slides were 
presented to, whether the presentation was given by the FDA or sponsor, and the number of 
slides in the presentation.
If you have any questions, you can reach me at lmsmith2@yahoo.com or at (919) 607-5844.
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Instructions, cont.
Code slides into one of the following seven categories: 
• Text 
• Diagram 
• Table
• Graph
• Table+graph
• Build slide
• Other  
Subcategorize graph slides and table+graph slides as:
• Bar graph (2D, horizontal) 
• Bar graph (2D, vertical) 
• Bar graph (3D, horizontal) 
• Bar graph (3D, vertical) 
• Stacked bar graph (2D, vertical)
• Stacked bar graph (3D, vertical)
• Line graph
• Kaplan-Meier curve 
• Pie chart (2D)
• Pie chart (3D) 
• Pictograph 
• Forest plot
• XY scatterplot
• Multiple graph, same type (specify) 
• Multiple-graph, mixed types (specify)
• Other
If ‗multiple-graph, same type‘ or ‗multiple-graph, mixed types‘ is selected, you will 
be asked to specify the type(s) of graphs.  Refer to the graphs using the same 
terminology listed here.  For example, if a slide contains a line graph and a 2D 
vertical bar graph, enter: ―Line graph, bar graph (2D, vertical),‖ not, ―Line graph, 2D 
vertical bar graph‖.  Separate graph types with a comma.  If the graphs are the same 
type, you need only list the graph once.  For example, if a slide has multiple line 
graphs, you need only enter ―Line graph,‖ not ―Line graph, line graph.‖  
Categorizes slides based on the content of the body of the slide, exclusive of slide 
title, background, and background graphic.  
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Text
Text slides contain: (a) only text, (b) text as the primary focus with 
diagram(s) or picture(s) serving as secondary visuals, or (c) text and 
diagrams/pictures in approximately a 50-50 ratio.
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Cardiovascul
arandRenalDrugsAdvisoryCommittee/ucm195971.htm
Example(s)
(a)
(b) (c)
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Diagram
Diagram slides contain diagrams or pictures as the primary focal point of 
the slide.  Although they may contain a lot of text, a schematic is clearly 
being used to convey an idea(s).
Example(s)
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Cardiovascul
arandRenalDrugsAdvisoryCommittee/ucm195971.htm;
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDr
ugsAdvisoryCommittee/ucm148865.htm
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Table
Table slides contain tables—―a systematic arrangement of data usually in 
rows and columns‖—either with or without accompanying text.  Slides 
that show text and/or bullets in table form will be excluded from this 
category; those slides will be coded as diagram/picture slides.  If the 
information displayed in the table could not have been displayed in 
graphical format, the slide is not a table slide. Only slides that show data
in table format meet the definition of a table slide .  
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinolog
icandMetabolicDrugsAdvisoryCommittee/ucm194913.htm
Example(s)
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Graph
Graph slides contain graphs—diagrams ―that represent the variation of a 
variable in comparison with that of one or more other variables‖—either 
with or without accompanying text.  
See ―subcategories‖ for example(s)
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Table+graph
Table+graph slides contain both a table(s) and a graph(s).
Example(s)
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinolog
icandMetabolicDrugsAdvisoryCommittee/ucm194913.htm
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Build slides
Build slides are nearly identical slides shown in a sequence.  Slides are 
often shown in such a series to emphasize or call attention to specific 
data.  It would be inappropriate to code each slide in the series as a 
separate slide as the series is usually perceived as one slide by the 
audience.  Every slide in this type of sequence will be coded as a ―build‖ 
slide except the final slide , which will be categorized appropriately.  
You will not recognize a build sequence until you move forward through 
the slides in a series.  In the example shown below, you will have coded 
slide CC-41 as a table slides before realizing it is part of a build.  This 
means you will have to go backwards and re-code the earlier slides in a 
build sequence as you realize the build nature of the series.
Example(s)
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinolog
icandMetabolicDrugsAdvisoryCommittee/ucm194913.htm
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Other
Slides that do not fall into any of the categories above.  Blank slides are 
included in this category.  Other than blank slides, there should be very 
few slides in this category.
Things to consider
Slides should be coded according to the definitions provided here.  If a 
slide is difficult to categorize, use your best judgment.  Think, ―what is 
the intent of this slide?‖ or ―what is the intent of this tabular format?‖.  
A note about screen grabs: screen grab slides may be coded as 
―diagram/picture slides‖ or may be coded as text, table, graph slides (as 
appropriate).  If it is clear that the intent of the screen grab was to show a 
picture of something (as in the case of a form or a journal article), code 
the slide as a picture/diagram slide.  If the intent was just to display the 
text/table/graph without emphasis on the fact that it is a picture, code the 
slide as appropriate.  Again, ask yourself, ―what is the intent of this 
screen grab?‖.
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Subcategories
for Graph and
Table+Graph Slides
77 
 
Bar graph (2D, horizontal)
A graph that uses the comparative length of rectangles, ovals, or some 
other shape to indicate the size of variables.  The shapes are displayed 
next to each other in a column along the Y axis and may or may not be 
adjacent.  The shapes are displayed horizontally and in two dimensions.  
Bars may or may include error bars.
Example(s)
Samples slides downloaded from: 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-
AllergyDrugsAdvisoryCommittee/ucm194063.htm
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Bar graph (2D, vertical)
A graph that uses the comparative length of rectangles, ovals, or some 
other shape to indicate the size of variables.  The shapes are displayed 
next to each other in a row along the X axis and may or may not be 
adjacent.  The shapes are displayed vertically and in two dimensions. 
Bars may or may not include error bars.
Example(s)
Samples slides downloaded from: 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinolog
icandMetabolicDrugsAdvisoryCommittee/ucm194913.htm
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Bar graph (3D, horizontal)
A graph that uses the comparative length of rectangles, ovals, or some 
other shape to indicate the size of variables.  The shapes are displayed 
next to each other in a column along the Y axis and may or may not be 
adjacent.  The shapes are displayed horizontally and in three dimensions.
Example(s)
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Bar graph (3D, vertical)
A graph that uses the comparative length of rectangles, ovals, or some 
other shape to indicate the size of variables.  The shapes are displayed 
next to each other in a row along the X axis and may or may not be 
adjacent.  The shapes are displayed vertically and in three dimensions.
Example(s)
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Stacked bar graph (2D, vertical)
A graph that uses the comparative length of rectangles, ovals, or some 
other shape to indicate the size of variables.  The shapes are placed on top 
of each other in a continuous stack. The stack is displayed vertically and 
in two dimensions.
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Cardiovascul
arandRenalDrugsAdvisoryCommittee/ucm195971.htm
Example(s)
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Stacked bar graph (3D, vertical)
A graph that uses the comparative length of rectangles, ovals, or some 
other shape to indicate the size of variables.  The shapes are placed on top 
of each other in a continuous stack. The stack is displayed vertically and 
in three dimensions.
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Cardiovascul
arandRenalDrugsAdvisoryCommittee/ucm195971.htm
Example(s)
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Line graph
Example(s)
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Cardiovascul
arandRenalDrugsAdvisoryCommittee/ucm195971.htm
A graph that plots data points along one axis.  The data points are 
connected by a line. Data points may or may not include error bars.
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Kaplan-Meier curve
Example(s)
Samples slides downloaded from: 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-
AllergyDrugsAdvisoryCommittee/ucm194063.htm
A statistical graph that plots the estimated amount of time it takes for a 
particular event to occur (time to event).  These graphs are recognizable 
by the stair-like progression of the plot lines.
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Pie chart (2D)
A chart that consists of a circle divided into two or more sections by radii 
of the circle.  The size of the sections indicates the size of the variables 
they represent.  The sections may or may not be pulled out from the ―pie‖ 
as a whole.  The sections of the pie are represented in two dimensions.
Example(s)
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDr
ugsAdvisoryCommittee/ucm195675.htm
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Pie chart (3D)
Example(s)
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinolog
icandMetabolicDrugsAdvisoryCommittee/ucm194913.htm
A chart that consists of a circle divided into two or more sections by radii 
of the circle.  The size of the sections indicates the size of the variables 
they represent.  The sections may or may not be pulled out from the ―pie‖ 
as a whole.  The sections of the pie are represented in three dimensions.
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Pictograph
A graph that displays geometric or human-shaped icons in relation to 
other icons to indicate the size of the variable(s) they represent.
Example(s)
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Peripheraland
CentralNervousSystemDrugsAdvisoryCommittee/ucm154399.htm
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Forest plot
A graph that plots data points and their confidence intervals along one 
axis.  The data points are usually plotted along a horizontal axis and 
stacked in a column, however, they may also be plotted along a vertical 
axis and appear in a row. 
Example(s)
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Cardiovascul
arandRenalDrugsAdvisoryCommittee/ucm195971.htm;
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Cardiovascul
arandRenalDrugsAdvisoryCommittee/ucm136947.htm
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XY scatterplot
Example(s)
A graph that displays data points plotted along both an X and Y axis.  The 
graph may or may not include a line of regression.
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Peripheraland
CentralNervousSystemDrugsAdvisoryCommittee/ucm191027.htm
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Multiple graph, same type 
Example(s)
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinolog
icandMetabolicDrugsAdvisoryCommittee/ucm194913.htm
A slide that shows two or more graphs of the same type.
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Multiple graph, mixed types 
Example(s)
Samples slides downloaded from: : 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinolog
icandMetabolicDrugsAdvisoryCommittee/ucm194913.htm
A slide that shows two or more graphs of different types.
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Other
Graph slides that do not fall into any of the categories above.
Note that mixed-type graphs, such those with both bars (similar to a bar 
graph) and lines (similar to a line graph) should be coded as ‗other‘.
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